Niagen Bioscience 8-K: earnings press release and presentation
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Niagen Bioscience, Inc. furnished an 8-K announcing it issued a press release with earnings for the quarter ended September 30, 2025, and posted a corporate presentation on its website.
The press release is included as Exhibit 99.1 and the presentation as Exhibit 99.2. The information in Items 2.02 and 7.01 is being furnished and is not deemed “filed” under the Exchange Act.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 2.02, 7.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2025
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 4, 2025, Niagen Bioscience, Inc. (the “Company”) issued a press release announcing its earnings for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 7.01. Regulation FD Disclosure.
On November 4, 2025, the Company released a corporate presentation which it made available on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2.
The information in this Item 7.01 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description | |||||||
99.1 | Press Release dated November 4, 2025 | |||||||
99.2 | Earnings Presentation of Niagen Bioscience, Inc. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NIAGEN BIOSCIENCE, INC. | ||||||||
Dated: November 4, 2025 | By: | /s/ OZAN PAMIR | ||||||
| Ozan Pamir | ||||||||
| Chief Financial Officer | ||||||||
| (principal financial officer and duly authorized on behalf of the registrant) | ||||||||
FAQ
What did NAGE disclose in this 8-K?
The company furnished its earnings press release for the quarter ended September 30, 2025, and a corporate presentation.
Which exhibits are included in Niagen Bioscience’s 8-K?
Exhibit 99.1 is the November 4, 2025 press release and Exhibit 99.2 is the earnings presentation.
Does this 8-K include financial results for NAGE?
It announces earnings via a press release (Exhibit 99.1), but the 8-K text itself does not list figures.
Is the information considered 'filed' or 'furnished'?
Items 2.02 and 7.01 are being furnished and are not deemed “filed” under the Exchange Act.
What period does the earnings announcement cover for NAGE?
It covers the quarter ended September 30, 2025.
Where can I access NAGE’s corporate presentation?
The company made it available on its website and attached it as Exhibit 99.2.